RELMADA THERAPEUTICS, INC. — Director's Dealing 2021

Jan 27, 2021

SEC Form 4/A — Form 4/A

Issuer: RELMADA THERAPEUTICS, INC. (RLMD)
CIK: 0001553643
Period of Report: 2021-01-22

Reporting Person: Kelly Paul Edward (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-01-22	Common Stock	S	1800	$35.43	Disposed	149580	Direct

Footnotes

F1: The sales reported on this Form 4 were effectuated pursuant to a Rule 10b51 trading plan adopted by the reporting person on December 22, 2020.

F2: The number of securities reported represents an aggregate number of shares sold in multiple open market transactions over a range of sales prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares sold by the Reporting Person at each separate price within the range.

F3: Sales price range from $35.04 to $35.98 per share, inclusive.